FCP
GILD icon

Fidelis Capital Partners’s Gilead Sciences GILD Stock Holding History

Fidelis Capital Partners’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$867K Buy
6,859
+1,162
+20% +$153K 0.05% 251
2026
Q1 		$794K Buy
5,697
+505
+10% +$70.7K 0.06% 244
2025
Q4 		$637K Buy
5,192
+206
+4% +$25K 0.05% 269
2025
Q3 		$553K Sell
4,986
-305
-6% -$34.7K 0.04% 281
2025
Q2 		$583K Buy
5,291
+575
+12% +$61.2K 0.05% 239
2025
Q1 		$487K Buy
4,716
+7
+0.1% +$722 0.05% 251
2024
Q4 		$463K Buy
4,709
+215
+5% +$19.4K 0.05% 266
2024
Q3 		$392K Buy
4,494
+268
+6% +$20.4K 0.05% 274
2024
Q2 		$313K Buy
4,226
+1,201
+40% +$80.1K 0.04% 280
2024
Q1 		$222K Buy
3,025
+500
+20% +$38.4K 0.03% 337
2023
Q4 		$205K Buy
+2,525
New +$196K 0.05% 313

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fidelis Capital Partners's GILD Position: Q2 2026 in Review

Fidelis Capital Partners increased its Gilead Sciences (GILD) stake by 20% in Q2 2026, buying an estimated $153K and bringing the position to 6,859 shares worth $867K. The position accounts for 0.05% of the portfolio, ranked #251.

Fidelis Capital Partners first reported a position in GILD in Q4 2023 and has held it in 11 quarters since. 2,291 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Fidelis Capital Partners held 6,859 shares of Gilead Sciences worth $867K as of Q2 2026.
  • Fidelis Capital Partners bought 1,162 Gilead Sciences shares in Q2 2026, an estimated $153K.
  • Gilead Sciences made up 0.05% of Fidelis Capital Partners's portfolio in Q2 2026, its #251 holding.
  • Fidelis Capital Partners first reported a position in Gilead Sciences in Q4 2023 and has held it in 11 quarters since.
  • 2,291 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Fidelis Capital Partners's 13F filing for Q2 2026, filed 13 Aug 2026.